Specifically, AT-I was shown to overcome eIF4E-mediated resistance in prostate cancer by inhibiting the Hsp27/eIF4E pathway, thereby enhancing the chemosensitizing effects of cabozantinib [73]. Here, EIF4E is linked to Familial prostate cancer.